Long‐term dienogest administration in patients with symptomatic adenomyosis

Kazuaki Neriishi, Tetsuya Hirata, Shinya Fukuda, Gentaro Izumi, Akari Nakazawa, Naoko Yamamoto, Miyuki Harada, Yaushi Hirota, Yasushi Hirota, Kaori Koga, Osamu Wada‐Hiraike, Osamu Wada-Hiraike, Tomoyuki Fujii, Yutaka Osuga
Journal of Obstetrics and Gynaecology Research · 2018 · vol. 44(8) , pp. 1439–1444 · doi:10.1111/jog.13674 · PMID:29845696 · W2807604334
article OA: closed CC0 ⤵ 53 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Long-term dienogest administration for symptomatic adenomyosis was effective and tolerable until menopause in two-thirds of patients, particularly those with type 2 adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: Adenomyosis is a common gynecological disorder that causes dysmenorrhea, hypermenorrhea and metrorrhagia. Previously, we reported that 24 weeks of dienogest treatment is highly effective for pain in symptomatic adenomyosis. Up to present, there is no report that describes treatment of adenomyosis with long-term dienogest administration for more than 2 years. In this retrospective cohort study, we investigated the course of long-term dienogest treatment in patients with symptomatic adenomyosis. METHODS: This is a retrospective cohort study. Dienogest was continuously administered at a dose of 2 mg daily for patients with symptomatic adenomyosis. The outcome of long-term administration of dienogest was investigated, and the characteristics of patients were compared between discontinued cases and long-term administration cases. RESULTS: Two patients were excluded from this study because of transfer to another hospital or discontinuation due to infertility treatment. Twelve of 18 patients (66.7%) received dienogest until menopause or for a period of >80 months. Four cases (22.2%) discontinued dienogest treatment because of severe metrorrhagia. In the discontinued cases because of severe metrorrhagia, the pain score for dysmenorrhea and serum CA125 level at baseline significantly elevated, and the hemoglobin level at baseline and the frequency of type 2 adenomyosis significantly decreased, compared to those with long-term use. Moreover, long-term dienogest use did not decrease the serum estradiol level. CONCLUSION: Our report suggests that dienogest is tolerable for long-term use until menopause and can be an alternative treatment option in some patients, especially those with type 2 adenomyosis, to avoid hysterectomy.

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrheainfertility

MeSH descriptors

Adenomyosis Hormone Antagonists Nandrolone Adenomyosis Adult Female Hormone Antagonists Hormone Antagonists Hormone Antagonists Humans Longitudinal Studies Middle Aged Nandrolone Nandrolone Nandrolone Nandrolone Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:43.094626+00:00
License: CC0 · commercial use OK